[Federal Register Volume 61, Number 156 (Monday, August 12, 1996)]
[Notices]
[Pages 41794-41795]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-20523]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces a forthcoming meeting of a public
advisory committee of the Food and Drug Administration (FDA). This
notice also summarizes the procedures for the meeting and methods by
which interested persons may participate in open public hearings before
FDA's advisory committees.
FDA has established an Advisory Committee Information Hotline (the
hotline) using a voice-mail telephone system. The hotline provides the
public with access to the most current information on FDA advisory
committee meetings. The advisory committee hotline, which will
disseminate current information and information updates, can be
accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory
committee is assigned a 5-digit number. This 5-digit number will appear
in each individual notice of meeting. The hotline will enable the
public to obtain information about a particular advisory committee by
using the committee's 5-digit number. Information in the hotline is
preliminary and may change before a meeting is actually held. The
hotline will be updated when such changes are made.
MEETING: The following advisory committee meeting is announced:
Food Advisory Committee
Date, time, and place. August 27 and 28, 1996, 8:15 a.m., Marriott
Hotel-Metro Center, Grand Ballroom Salons A, B, and C, 775 12th St.
NW., Washington, DC.
Type of meeting and contact person. Open committee discussion,
August 27, 1996, 8:15 a.m. to 3 p.m.; open public hearing, 3 p.m. to 5
p.m., unless participation does not last that long; open committee
discussion, August 28, 1996, 8:15 a.m. to 4 p.m.; Lynn A. Larsen,
Center for Food Safety and Applied Nutrition (HFS-5), Food and Drug
Administration, 200 C St. SW., Washington, DC 20204, 202-205-4727, or
Catherine M. DeRoever (address above), Advisory Committee Staff (HFS-
22), 202-205-4251, FAX 202-205-4970, or FDA Advisory Committee
Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), Food Advisory Committee, code 10564. Please call the hotline for
information concerning any possible changes.
General function of the committee. The committee provides advice on
emerging food safety, food science, and nutrition issues that FDA
considers of primary importance in the next decade.
-Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person by close of business August 21, 1996, and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time required to
make their comments. If necessary, comments may be limited to 5
minutes.
-Open committee discussion. The Food Advisory Committee and the
Ephedra Working Group will discuss the actions and recommendations made
by the working group during its October 11 and 12, 1995, meeting.
Additional information that has become available to FDA since that time
will also be presented during the meeting. The committee will be asked
to consider the original working group's recommendations in light of
this new information.
-Under 21 CFR 14.20 and 14.35, interested persons may submit
written information or views on the matter(s) before the committee.
Voluminous data are to be accompanied by a summary. Submissions must be
made to the Executive Secretary and not directly to any committee
members. Substantive submissions received at least 3 weeks prior to a
meeting may be included in members' briefing materials; submissions
received later will be distributed at the committee meeting. All
submissions that include copyrighted materials must be accompanied by
documented permission for duplication and distribution at no copyright
expense to FDA.
-At least 50 copies of each submission must be provided; sufficient
additional copies may be requested by the agency for distribution to
the public at a meeting. Fewer copies of voluminous submissions will be
required; only summaries of such submissions will be provided to
committee members, with complete copies of submissions being made
available for circulation among committee members and for viewing by
the public at a meeting.
-More detailed information regarding the meeting agenda that may
become available prior to the meeting will be provided to the public
via the 800 number given above.
FDA public advisory committee meetings may have as many as four
separable portions: (1) An open public hearing, (2) an open committee
discussion, (3) a closed presentation of data, and (4) a closed
committee deliberation. Every advisory committee meeting shall have an
open public hearing portion. Whether or not it also includes any of the
other three portions will depend upon the specific meeting involved.
There are no closed portions for the meetings announced in this notice.
The dates and times reserved for the open portions of each committee
meeting are listed above.
The open public hearing portion of each meeting shall be at least 1
hour long unless public participation does not last that long. It is
emphasized, however, that the 1 hour time limit for an open public
hearing represents a minimum rather than a maximum time for public
participation, and an open public hearing may last for whatever longer
period the committee chairperson determines will facilitate the
committee's work.
Public hearings are subject to FDA's guideline (subpart C of 21 CFR
part 10) concerning the policy and procedures for electronic media
coverage of FDA's public administrative proceedings, including hearings
before public advisory committees under 21 CFR part 14. Under 21 CFR
10.205, representatives of the electronic media may be permitted,
subject to certain limitations, to videotape, film, or otherwise record
FDA's public administrative proceedings, including presentations by
participants.
Meetings of advisory committees shall be conducted, insofar as is
practical, in accordance with the agenda published in this Federal
Register notice. Changes in the agenda will be announced at the
beginning of the open portion of a meeting.
Any interested person who wishes to be assured of the right to make
an oral presentation at the open public hearing portion of a meeting
shall inform the contact person listed above, either orally or in
writing, prior to the meeting. Any
[[Page 41795]]
person attending the hearing who does not in advance of the meeting
request an opportunity to speak will be allowed to make an oral
presentation at the hearing's conclusion, if time permits, at the
chairperson's discretion.
The agenda, the questions to be addressed by the committee, and a
current list of committee members will be available at the meeting
location on the day of the meeting.
Transcripts of the open portion of the meeting may be requested in
writing from the Freedom of Information Office (HFI-35), Food and Drug
Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857,
approximately 15 working days after the meeting, at a cost of 10 cents
per page. The transcript may be viewed at the Dockets Management Branch
(HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23,
Rockville, MD 20857, approximately 15 working days after the meeting,
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary
minutes of the open portion of the meeting may be requested in writing
from the Freedom of Information Office (address above) beginning
approximately 90 days after the meeting.
This notice is issued under section 10(a)(1) and (2) of the Federal
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR
part 14) on advisory committees.
Dated: August 6, 1996.
David A. Kessler,
Commissioner of Food and Drugs.
[FR Doc. 96-20523 Filed 8-9-96; 8:45 am]
BILLING CODE 4160-01-F
